Supplementary Data — Amubarvimab/romlusevimab for COVID-19: real-time meta analysis of 4 studies

@CovidAnalysis, December 2025, Version 4V4
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ACTIV-2/A5401 Evering (DB RCT) 91% 0.09 [0.01-0.70] death 1/390 11/390 Improvement, RR [CI] Treatment Control ACTIV-2/A5401 Evering (DB RCT) -20% 1.20 [0.83-1.75] PASC 53/390 44/390 ACTIV-2/A5401 Evering (DB RCT) 61% 0.39 [0.22-0.68] hosp. 16/390 41/390 ACTIV-2/A5401 Evering (DB RCT) 67% 0.33 [0.19-0.56] death/hosp. 17/390 52/390 ACTIV-3/TICO Self (DB RCT) -15% 1.15 [0.54-2.41] death 15/176 13/178 ACTIV-3/TICO Self (DB RCT) 7% 0.93 [0.76-1.14] no recov. 21/176 27/178 ACTIV-3/TICO Self (DB RCT) 0% 1.00 [0.68-1.47] no recov. 173 (n) 178 (n) Yalan -71% 1.71 [0.69-4.25] death 12/170 7/170 Yalan -8% 1.08 [0.74-1.58] ICU 42/170 39/170 Yalan 8% 0.92 [0.87-0.97] hosp. time 170 (n) 170 (n) Yalan 7% 0.93 [0.89-0.98] viral time 170 (n) 170 (n) Qu (ICU) 46% 0.54 [0.29-1.04] death 47 (n) 47 (n) ICU patients Qu (ICU) 4% 0.96 [0.57-1.64] viral+ 47 (n) 47 (n) ICU patients Amubarvimab COVID-19 outcomes c19early.org December 2025 Favors amubarvimab Favors control
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.